大剂量重组人红细胞生成素治疗肾性贫血的临床疗效被引量：6

下载PDF

导出

摘要目的探讨大剂量重组人红细胞生成素(rHuEPO)治疗尿毒症患者肾性贫血的疗效和不良反应。方法选择我院符合标准的慢性肾功能不全尿毒症期合并肾性贫血且病情稳定患者22例,随机分为观察组和对照组各11例,观察组给予10000 U rHuEPO,皮下注射,每周1次。对照组给予3000 U rHuEPO,皮下注射,每周2次。比较两组患者的疗效和治疗前、后血小板计数(PLT)和谷氨酰转肽酶(GGT),同时记录不良反应。结果两组患者临床疗效间差异有统计学意义(P<0.05);两组患者治疗前后PLT、GGT检测结果比较差异均无统计学意义(P>0.05)。两组各有1例血压较前明显升高,均未见其他不良反应。结论大剂量rHuEPO每周1次治疗肾性贫血疗效较好,同时减少了患者的注射次数,提高了患者的依从性,且安全,值得临床推广应用。

作者孙珉丹王飞宇陈志

机构地区吉林大学第一医院肾内科吉林大学第一医院口腔科

出处《中国全科医学》 CAS CSCD 2008年第21期1989-1989,共1页 Chinese General Practice

关键词红细胞生成素重组贫血尿毒症

分类号 R556.9 [医药卫生—血液循环系统疾病]

引文网络
相关文献

参考文献4

1彭涛,胡昭,王荣,王群.重组人促红细胞生成素治疗肾性贫血的多中心临床研究[J].中国药房,2007,18(26):2040-2041. 被引量：13
2Munugalavadla V, Kapur R. Role of c - Kit and erythropoietin receptor in erythropoiesis[J]. Crit Rev Oncol Hematol, 2005, 54 (1): 63-75.
3孙治坤,陈生弟.促红细胞生成素抗神经元凋亡的信号传导通路[J].中国药理学通报,2006,22(12):1429-1432. 被引量：8
4Piccoli A. Subcutaneous epoetinalpha every one, two, and three weeks in renal anemia [J]. ] Nephrol, 2002, 15 (5): 565.

二级参考文献30

1张萍,梁劲松.大剂量促红细胞生成素治疗肾性贫血的疗效观察[J].中国药房,2005,16(13):1009-1010. 被引量：7
2[1]Kilic E,Kilic U,Soliz J,et al.Brain-derived erythropoietin protects from focal cerebral ischemia by dual activation of ERK-1/-2and Akt pathways[J].FASEB J,2005,19(14):2026 -8.
3[2]Spandou E,Soubasi V,Papoutsopoulou S,et al.Erythropoietin prevents hypoxia/ischemia-induced DNA fragmentation in an experimental model of perinatal asphyxia[J].Neurosci Lett,2004,366(1):24 -8.
4[3]Kaptanoglu E,Solaroglu I,Okutan O,et al.Erythropoietin exerts neuroprotection after acute spinal cord injury in rats:effect on lipid peroxidation and early ultrastructural findings[J].Neurosurg Rev,2004,27(2):113 -20.
5[4]Yatsiv I,Grigoriadis N,Simeonidou C,et al.Erythropoietin is neuroprotective,improves functional recovery,and reduces neuronal apoptosis and inflammation in a rodent model of experimental closed head injury[J].FASEB J,2005,19(12):1701 -3.
6[5]Bartesaghi S,Marinovich M,Corsini E,et al.Erythropoietin:a novel neuroprotective cytokine[J].Neurotoxicology,2005,26(5):923-8.
7[6]Genc S,Koroglu T F,Genc K.Erythropoietin and the nervous system[J].Brain Res,2004,1000 (1-2):19-31.
8[7]Siren A L,Knerlich F,Poser W,et al.Erythropoietin and erythropoietin receptor in human ischemic/hypoxic brain[J].Acta Neuropathol(Berl),2001,101(3):271 -6.
9[8]Eid T,Brines M L,Cerami A,et al.Increased expression of erythropoietin receptor on blood vessels in the human epileptogenic hippocampus with sclerosis[J].J Neuropathol Exp Neurol,2004,63(1):73 -83.
10[9]Chang G H,Barbaro N M,Pieper R O.Phosphatidylserine-dependent phagocytosis of apoptotic glioma cells by normal human microglia,astrocytes,and glioma cells[J].Neuro-oncol,2000,2(3):174-83.